Daybue (trofinetide) prior authorization for Rett syndrome
Customize your policy alerts
Sign up for all UnitedHealthcare policy alerts
Know when UnitedHealthcare releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and medical necessity criteria for Daybue (trofinetide) for treatment of Rett syndrome in beneficiaries of UnitedHealthcare. It affects prescribers and pharmacies seeking authorization for initial and continued therapy.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial Authorization
Approved when ALL of the following are met:
Authorization issued for 12 months.
Reauthorization
Reauthorization approved when ALL of the following are met:
Authorization issued for 12 months.
Coverage for Daybue (trofinetide) may be subject to limits beyond the clinical criteria in this policy. State mandates can impose additional coverage requirements, and federal regulatory requirements and the member’s specific benefit plan may further restrict or define coverage. Where applicable, other UnitedHealthcare policies and utilization management programs may also affect authorization decisions. Providers should confirm member benefits and any state- or plan-level requirements when requesting prior authorization.
Initial Therapy
Initial therapy coverage rules
Authorization issued for 12 months.
Reauthorization
Reauthorization rules
Authorization issued for 12 months; prescriber specialty or documented consultation should be noted as applicable.
Prescriber & Provider Requirements
Prior authorization required; 12‑month approval
Prior authorization is required for Daybue (trofinetide). When the initial coverage criteria are met, authorization will be issued for 12 months.
Automated and claim‑based approvals permitted
UnitedHealthcare may use automated approval and re-approval processes and may approve based on prior claim/medication history, diagnosis codes, and/or claim logic in lieu of other documentation per program rules.
- Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Approvals may be based solely on previous claim/medication history, diagnosis codes (ICD‑10) and/or claim logic.
Required documentation for initial authorization and reauthorization
Document the diagnosis of Rett syndrome either by the listed clinical signs or by a confirmed MECP2 gene mutation; for reauthorization, document a positive clinical response to Daybue. Note the prescribing provider specialty or consultation with the required specialist.
- Evidence of RTT by clinical criteria: pattern of development → regression → recovery/stabilization; loss of purposeful hand skills; loss of spoken language; repetitive hand movements; gait abnormalities.
- OR documented MECP2 gene mutation.
- For reauthorization, documentation of positive clinical response to Daybue therapy is required.
- Prescriber must be (or consult with) a geneticist, a pediatrician who specializes in childhood neurological or developmental disorders, or a neurologist.
Denial triggers for missing diagnosis or required prescriber specialty
Requests may be denied if there is no documented RTT diagnosis by clinical criteria or confirmed MECP2 mutation, or if the prescriber specialty/consultation requirement is not met.
- Absence of documentation of the specified clinical signs or a confirmed MECP2 mutation.
- Lack of prescribing by, or consultation with, an approved specialist (geneticist; pediatric neurologist/developmental pediatrician; or neurologist).
Background
Daybue (trofinetide) is a synthetic analog of the amino‑terminal tripeptide of insulin‑like growth factor‑1 (IGF‑1) and is indicated for the treatment of Rett syndrome (RTT) in patients aged 2 years and older. Rett syndrome is a neurodevelopmental disorder characterized by a developmental pattern of regression with loss of purposeful hand skills and spoken language, repetitive hand movements, and gait abnormalities; diagnosis can be made clinically based on these characteristic signs or by confirmation of an MECP2 gene mutation.
Key Definitions
Step Therapy / Automated Approval Processes
| Step | Program rule | Documentation accepted |
|---|---|---|
| 1 | Program may use prior claims/medication history and automated approval/re-approval processes as part of step therapy determinations; use varies by program and therapeutic class. | Previous claim/medication history, diagnosis codes (ICD-10), and/or claim logic may be accepted in lieu of other documentation. |
Quantity Limits
Site-of-Care and Utilization Management
No site‑of‑care mandate; program rules may vary
No specific site‑of‑care requirement is stated in this policy; however, utilization management rules and use of automated approval processes may vary by program.
- Policy does not mandate a particular setting for Daybue administration.
- Program‑level utilization management and automated approval logic may differ across programs or therapeutic classes.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.